<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03343431</url>
  </required_header>
  <id_info>
    <org_study_id>iTAP-2</org_study_id>
    <nct_id>NCT03343431</nct_id>
  </id_info>
  <brief_title>Antiviral Prophylaxis and Infant Vaccination to Prevent Perinatal Hepatitis B Infection</brief_title>
  <official_title>A Maternal Short Course of Tenofovir Disoproxil Fumarate and Infant Vaccine to Prevent Mother-to-child Transmission of Hepatitis B Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Lao PDR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherche pour le Developpement</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most new hepatitis B virus (HBV) infections are acquired perinatally. In this study, pregnant&#xD;
      women with HBsAg and HBeAg will receive tenofovir disoproxil fumarate during the last&#xD;
      trimester of pregnancy and for two months following delivery. Their infants will receive&#xD;
      hepatitis B (HB) immunization, starting with a first dose soon after birth. We hypothesize&#xD;
      that the risk of mother-to-child transmission of HBV will be lower than 2%. The results of&#xD;
      the study will help define policy to manage HBV infected pregnant women to prevent perinatal&#xD;
      transmission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective multi-center, multi-country (Thailand and Lao PDR), open-label, single&#xD;
      arm clinical trial in HBsAg and HBeAg positive pregnant women (from 28 weeks until one year&#xD;
      postpartum) and their infants (until 18 months of age). Pregnant women with HBsAg and HBeAg&#xD;
      will receive tenofovir disoproxil fumarate 300 mg once daily from 28 weeks of pregnancy until&#xD;
      two months postpartum. Their infants will receive hepatitis B (HB) immunization, starting&#xD;
      with the first dose soon after birth.&#xD;
&#xD;
      The study aims to show that substituting maternal antiviral treatment for infant HBIg can be&#xD;
      favorably considered in settings where HBIg plus vaccine has been used as well as in settings&#xD;
      where only vaccine is used. A significant improvement over the standard HBIg + vaccine&#xD;
      strategy would be that adding an antiviral strategy results in less than 2% transmission. A&#xD;
      total of 499 women and their infants will be enrolled in public hospitals in Thailand and Lao&#xD;
      PDR.&#xD;
&#xD;
      The study will be monitored by a Data and Safety Monitoring Board (DSMB) at least annually.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants receive the intervention</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infant hepatitis B infection status</measure>
    <time_frame>Six months of age</time_frame>
    <description>HBsAg positive confirmed by PCR detection of HBV DNA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal HBV DNA changes</measure>
    <time_frame>From enrollment until end of study treatment scheduled 2 months after delivery</time_frame>
    <description>Description of the effect of tenofovir disoproxil fumarate on maternal HBV DNA levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant levels of anti-HBs antibodies</measure>
    <time_frame>At 1, 2, 4, 6, and 12 months of age</time_frame>
    <description>Levels of anti-HBs antibodies in infants in the absence of HBIg administration at birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV infection status in all infants regardless of maternal response to study treatment</measure>
    <time_frame>At 6 months of age</time_frame>
    <description>HBsAg positive confirmed by PCR detection of HBV DNA in all infants, i.e. including those born to women with unsatisfactory virological response to study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>From enrollment until 12 months postpartum</time_frame>
    <description>Occurrence of maternal serious adverse events (ICH SAEs) including DAIDS grade 4 signs and symptoms regardless of their relatedness to the study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>From birth until 12 months of age</time_frame>
    <description>Occurrence of infant serious adverse events (ICH SAEs) including DAIDS grade 4 signs and symptoms regardless of their relatedness to the study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm live births</measure>
    <time_frame>Delivery</time_frame>
    <description>Proportion of neonates born alive before 37 weeks of pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low birth weight</measure>
    <time_frame>Delivery</time_frame>
    <description>Proportion of neonates born alive with birth weight of 2,499 g or less, regardless of gestational age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active or previous transient infection in children</measure>
    <time_frame>At 18 months of age</time_frame>
    <description>Detection of anti-HBc antibodies among all infants</description>
  </secondary_outcome>
  <enrollment type="Actual">504</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Pregnancy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-HBV antiviral prophylaxis</intervention_name>
    <description>Tenofovir disoproxil fumarate (TDF), one 300 mg tablet once a day from 28 weeks' gestation through two months postpartum</description>
    <other_name>tenofovir disoproxil fumarate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Negative HIV antibody test during current pregnancy&#xD;
&#xD;
          -  Positive HBsAg test during current pregnancy&#xD;
&#xD;
          -  Positive HBeAg using a rapid test during current pregnancy&#xD;
&#xD;
          -  Absence of clinical symptoms of liver disease&#xD;
&#xD;
          -  Gestational age of 28 weeks (+/- 7 days) based on the obstetrician judgment guided by&#xD;
             the review of the date of last menstruation period.&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  Agreeing to bring her infants(s) at the planned study visits at one of the study site&#xD;
             until the last visit (18 months after birth) and to inform the site investigators if&#xD;
             plans to move to another place and not be able to return to the clinic&#xD;
&#xD;
          -  Understand the need for adequate infant immunization for her infant(s) and accept that&#xD;
             blood draws will be performed to determine the infant HBV infection status&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of anti-HBV antivirals at any time during the last 9 months&#xD;
&#xD;
          -  Known liver cirrhosis or evidence of hepatocellular carcinoma&#xD;
&#xD;
          -  Creatinine clearance &lt;50 ml/min, calculated using the Cockcroft-Gault formula&#xD;
&#xD;
          -  Confirmed dipstick proteinuria &gt;1+ (&gt;30 mg/dL) or normoglycemic glycosuria&#xD;
&#xD;
          -  Evidence of pre-existing fetal anomalies incompatible with life&#xD;
&#xD;
          -  Any concomitant condition or treatment that, in the view of the clinical site&#xD;
             investigator, would contraindicate participation or compromise adherence to treatment&#xD;
             and satisfactory follow up in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gonzague Jourdain, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recherche pour l e Développement</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Champasak Hospital</name>
      <address>
        <city>Champasak</city>
        <country>Lao People's Democratic Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luang Prabang Provincial Hospital</name>
      <address>
        <city>Luang Prabang</city>
        <country>Lao People's Democratic Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Savannakhet Provincial hospital</name>
      <address>
        <city>Savannakhet</city>
        <country>Lao People's Democratic Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sayaboury Hospital</name>
      <address>
        <city>Sayaboury</city>
        <country>Lao People's Democratic Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>103 Hospital</name>
      <address>
        <city>Vientiane</city>
        <country>Lao People's Democratic Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahosot Hospital</name>
      <address>
        <city>Vientiane</city>
        <country>Lao People's Democratic Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mother and Newborn Hospital</name>
      <address>
        <city>Vientiane</city>
        <country>Lao People's Democratic Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Setthathirath Hospital</name>
      <address>
        <city>Vientiane</city>
        <country>Lao People's Democratic Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Kham Hospital</name>
      <address>
        <city>Chiang Kham</city>
        <state>Phayao</state>
        <zip>56110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nopparat Rajathanee Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10230</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prapokklao Hospital</name>
      <address>
        <city>Chanthaburi</city>
        <zip>22000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Promotion Center Region 1</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50100</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakornping Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50180</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiangrai Prachanukroh Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonburi Hospital</name>
      <address>
        <city>Chon Buri</city>
        <zip>20000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banglamung Hospital</name>
      <address>
        <city>Chon Buri</city>
        <zip>20150</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lampang Hospital</name>
      <address>
        <city>Lampang</city>
        <zip>52000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lamphun Hospital</name>
      <address>
        <city>Lamphun</city>
        <zip>51000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samutprakarn Hospital</name>
      <address>
        <city>Samut Prakan</city>
        <zip>10280</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samutsakhon Hospital</name>
      <address>
        <city>Samut Sakhon</city>
        <zip>74000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lao People's Democratic Republic</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut de Recherche pour le Developpement</investigator_affiliation>
    <investigator_full_name>GONZAGUE JOURDAIN</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Hepatitis B eAg</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We are willing to share our data with other investigators, for example for meta-analysis, in order to answer important research questions requiring large datasets, after completion of the original research plan including substudies. Data-sharing agreements will include: an approval of the research plan by appropriate ethics committees, a commitment to using data for research purposes only and to securing the data or/and the samples using appropriate methods. We will consult as needed with the funding agency the practical aspects of data sharing.&#xD;
Data used for publications will be released in a timely manner. De-identified study data could be accessible through a website that allows querying such as the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Data and Specimen Hub or DASH (dash.nichd.nih.gov/).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>At the same time as related publications</ipd_time_frame>
    <ipd_access_criteria>See Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Data and Specimen Hub or DASH</ipd_access_criteria>
    <ipd_url>https://dash.nichd.nih.gov</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03343431/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03343431/ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

